Endocrine and metabolic parameters before onset of rGH treatment: potential predictive factors of rGH response in children born SGA? Results from cohort of Nancy, France



Authors: E. RENARD, C. LEGAGNEUR, J. AUGER, B. LEBON LABICH, C. BAUMANN, B. LEHEUP Endocrinology Unit, Children Hospital, University Hospital of Nancy, France



CONTEXT:

- Children born Small For Gestational Age (SGA) without catch up at 4 years can benefit of rGH treatment to improve adult final height
- Great variability of response is observed: 15 % of unsatisfactory response (Mairona *et al.*, 2009)
- Predictive factors described in literature : age at start of treatment, midparental height, rGH dose, bone age retardation, IGF1 levels ... (Ranke *et al.*, 2003; Ranke *et al.*, 2009)
- -=> We analyze the effects of **pretherapeutic data** such as **weight evolution** during first years of life, before onset of treatment, on rGH response in children born SGA.

MATERIAL AND METHOD:

- Retrospective and monocentric study in Nancy, France
- Children born SGA, treated by rGH since at least one 1 year in endocrinology unit of University Hospital of Nancy are included
- Amplitude of rGH response is defined as variation of height (DS) at 1 year, 2 years of treatment, at the end of treatment, and at adult final height
- Regression analysis, bivariate and multivariate, were performed to calculate regression coefficient (r) for each variable studied

RESULTS:

91 children were included.

Table 1: Clinical cohort description at start of rGH treatment

	Mean	Median	Standard deviation	
Gestational Age	37,8	39	3	
Lenght at birth SD	-3,1	-2,8	1	
Midparental height	162	162,5	11,9	
Midparental height SD	-0,9	-0,9	0,9	
Age at start of treatment	7,5	6,9	3,2	
Height SD	-3,3	-3,2	0,7	
BMI	15,02	14,9	1,9	
BMI SD	-0,8	-0,9	1,4	

<u>Pretherapeutic factors associated with amplitude of rGH response</u> (bivariate analysis):

- At 1 year of treatment (n=91):
 - Paternal height : r = 0.03, p = 0.0003
 - Height (DS):
 - At 9 months: r = -0.09; p = 0.01;
 - Between 2 and 3 years : r = -0.1; p = 0.035;
 - Between 3 and 4 years : r = -0.12; p = 0.032
 - Age at onset of rGH : r = -0,003, p = 0,0103
 - IGF-1 level before rGH : r = -0,001, p = 0,0199
 - Bone age at onset of rGH : r = -0.08, p = 0.0009
- At 2 years of treatment (n=82):
 - Paternal height : r = 0.02; p = 0.0386
 - Pretherapeutic TSH : r = 0.09; p = 0.0449
 - Height (DS):
 - At 9 months : r = -0.14; p = 0.028
 - Between 2 and 3 years : r = -0.15; p = 0.019
 - Between 3 and 4 years : r = -0.25; p = 0.019
 - IGF-1 level before rGH : r = -0,004; p = 0,002
 - Age at onset of rGH : r = -0.01; p = 0.0033
 - Bone age at onset of rGH : r = -0.12; p = 0.0005
 - Height at onset of rGH : r = -0.31; p = 0.0035

Table 2: rGH response after 1 year, 2 years and at the end of treatment

	n	Mean	Median	Standard deviation
Height SD after 1 year of treatment	87	-2,6	2,6	0,8
Height SD gain after 1 year of treatment	90	0,8	0,7	0,7
Height SD gain after 2 years of treatment	80	-2,2	-2,1	0,8
Height SD gain after 2 years of treatment	80	1,1	0,6	1
Height SD gain at the end of treatment	42	-2,1	-2	0,8
Height SD gain at the end of treatment	42	1,2	1,2	1,2
Adult final height SD	16	-2,7	-2,8	1,3
Height SD gain at adult final height	16	0,4	0,3	1,4

At the end of treatment (n=42):

- Bone age retardation : r = 0.04; p = 0.0046
- Bone age at onset of rGH : r = -0.14; p = 0.034
- Height (SD) between 2 and 3 years : r = 0,42; p = 0,004
- Height (SD) at onset of rGH : r = -0.57; p = 0.0012
- At adult final height (n=16):
 - Pretherapeutic total cholesterol : r = 1,64; p = 0,0341
 - Pretherapeutic cortisol : r = 0,02; p = 0,0217
 - T4 at onset of rGH: r = -0.31; p = 0.0417

<u>Pretherapeutic factors associated with amplitude of rGH response</u> (multivariate analysis):

At 2 years of treatment: TSH before onset of rGH: r = 1,1;
 p = 0,0204

CONCLUSION:

- Weight evolution before onset of rGH is not associated with rGH response in our study.
- This study highlights potential role of **thyroid hormone** in rGH response in children born SGA: SGA phenotype and rGH response may be linked to a **global hormonal resistance**.
- Others results are consistent with literature such at age at start of treatment, IGF-1 level, bone age,...

BIBLIOGRAPHY:

Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. 2009 Sep;124(3):e519-31.

Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, Wilton P, Price DA; KIGS International Board. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003 Jan;88(1):125-31.

Ranke MB, Lindberg A, Predicting growth in response to growth hormone treatment. Growth Horm IGE Pos. 2009 Feb;19(1):1-11

Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2009 Feb;19(1):1-11.









